Observational Study of Somatropin Treatment in Children - Full Text View

Purpose

GeNeSIS is an open-label, multinational, multicenter, observational study to evaluate the safety and effectiveness of Humatrope treatment.

GeNeSIS is a modular program that includes:

Core study: Evaluating the safety and effectiveness of Humatrope in the observational setting
Genetic Analysis Sub-study: Investigating the genetic defects underlying growth hormone (GH) deficiency and non-GH-deficient growth disorders
Growth Prediction Sub-study: Working to validate and refine specific models to accurately predict growth response to GH
SHOX Deficiency Sub-study: Elucidating the clinical, endocrine and radiological features of patients with SHOX deficiency due to loss of, or mutation in the SHOX gene (including patients with Turner syndrome)
Neoplasia Sub-study: To characterize the natural history of neoplastic disease, especially in relation to recurrence/progression of primary neoplasia or development of secondary neoplasia in children with a history of neoplasia

Condition	Intervention
Dwarfism, Growth Hormone Deficiency Turner Syndrome Infant, Small for Gestational Age SHOX Protein, Human	Drug: Somatropin (rDNA origin)


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

Resource links provided by NLM:

Genetics Home Reference related topics: Turner syndrome isolated growth hormone deficiency metatropic dysplasia pseudoachondroplasia

Drug Information available for: Somatropin

Genetic and Rare Diseases Information Center resources: Growth Hormone Deficiency Isolated Growth Hormone Deficiency Turner Syndrome Gonadal Dysgenesis Hypopituitarism

U.S. FDA Resources

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:

Standardized Incidence Ratio for Type 2 Diabetes Mellitus in Somatropin-Treated Children [ Time Frame: Year 15 ]
Standardized Incidence Ratio for De Novo Cancer in Somatropin-Treated Children [ Time Frame: Year 15 ]
Baseline Height, Final Height, Height Gain in Somatropin-Treated Children [ Time Frame: Baseline through Year 15 ]

Secondary Outcome Measures:

Percentage of Participants with Defects in Genes Associated with Pituitary Development [ Time Frame: Baseline through Year 15 ]
Predicted First Year Height Gain Versus Actual First Year Height Gain [ Time Frame: Baseline through Year 15 ]
Change from Baseline to Final Height in Anthropometric Measures for Participants with SHOX Deficiency [ Time Frame: Baseline, Year 15 ]
Percentage of Participants with Recurrent Tumors and Second Neoplasms [ Time Frame: Baseline through Year 15 ]
Percentage of Participants with De Novo Neoplasms [ Time Frame: Baseline through Year 15 ]
Standardized Incidence Ratio for Diabetes Mellitus in Somatropin-Treated Children with Different Short Stature Diagnoses [ Time Frame: Baseline through Year 15 ]

Biospecimen Retention: Samples With DNA

If patient consented a DNA sample is kept until the end of the study


Enrollment:	22929
Study Start Date:	April 1999
Study Completion Date:	September 2015
Primary Completion Date:	September 2015 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
Treated Patients treated with somatropin for improvement of growth	Drug: Somatropin (rDNA origin) Dose, frequency and duration at discretion of attending physician. Other Names: Humatrope LY137998
Untreated Untreated patients with presence or history of neoplastic disease evaluated for endocrine or growth disorder or with any SHOX deficiency related disorder

Eligibility


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Clinics and private practices

Criteria

Inclusion Criteria:

All patients participating in GeNeSIS must be enrolled in the core study. Patients for whom written consent to release information is provided may enter the core study if they meet any of the following inclusion guidelines:

Treatment with Humatrope for improvement of growth.
No treatment with somatropin in patients with a history of neoplasia or in those with any SHOX-related disorder.

Exclusion Criteria:

Patients with closed epiphyses are not eligible for GeNeSIS entry. However, patients may remain in the study if epiphyseal closure occurs during study participation.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01088412

Sponsors and Collaborators

Eli Lilly and Company

Investigators


Study Director:	Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)	Eli Lilly and Company

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Blum WF, Deal C, Zimmermann AG, Shavrikova EP, Child CJ, Quigley CA, Drop SL, Cutler GB Jr, Rosenfeld RG. Development of additional pituitary hormone deficiencies in pediatric patients originally diagnosed with idiopathic isolated GH deficiency. Eur J Endocrinol. 2013 Nov 22;170(1):13-21. doi: 10.1530/EJE-13-0643. Print 2014 Jan.

Deal C, Hasselmann C, Pfäffle RW, Zimmermann AG, Quigley CA, Child CJ, Shavrikova EP, Cutler GB Jr, Blum WF. Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growth hormone deficiency: data from an international observational study. Horm Res Paediatr. 2013;79(5):283-92. doi: 10.1159/000350829. Epub 2013 May 16.

Child CJ, Zimmermann AG, Scott RS, Cutler GB Jr, Battelino T, Blum WF; GeNeSIS International Advisory Board. Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program. J Clin Endocrinol Metab. 2011 Jun;96(6):E1025-34. doi: 10.1210/jc.2010-3023. Epub 2011 Apr 13. Erratum in: J Clin Endocrinol Metab. 2011 Aug;96(8):2624.


Responsible Party:	Eli Lilly and Company
ClinicalTrials.gov Identifier:	NCT01088412 History of Changes
Other Study ID Numbers:	2712 B9R-EW-GDFC ( Other Identifier: ELI Lilly and Company )
Study First Received:	February 25, 2010
Last Updated:	October 23, 2015

Additional relevant MeSH terms:


Dwarfism, Pituitary Dwarfism Turner Syndrome Gonadal Dysgenesis Primary Ovarian Insufficiency Bone Diseases, Developmental Bone Diseases Musculoskeletal Diseases Bone Diseases, Endocrine Hypopituitarism Pituitary Diseases Hypothalamic Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases	Endocrine System Diseases Disorders of Sex Development Urogenital Abnormalities Sex Chromosome Disorders of Sex Development Heart Defects, Congenital Cardiovascular Abnormalities Cardiovascular Diseases Heart Diseases Congenital Abnormalities Sex Chromosome Disorders Chromosome Disorders Genetic Diseases, Inborn Gonadal Disorders Ovarian Diseases Adnexal Diseases

ClinicalTrials.gov processed this record on August 23, 2017

Observational Study of Somatropin Treatment in Children (GeNeSIS)